● Calls for the study of adverse events following immunization (e.g., fever and seizures) to see if they increase autism risk.
● Calls for an external expert committee to consider “strengths and weaknesses, ethical issues and feasibility of examining outcomes in unvaccinated, vaccine delayed and vaccinated children.”
● Calls for the inclusion of autism as an outcome in the vaccine study.
● Calls for more research on “the possible occurrence of ASD in a small number of children subsequent to MMR vaccination” especially given “recent research around the incidence of mitochondrial dysfunction in children with an ASD phenotype.”
● Calls for studying adverse vaccine reactions in subsets of the ASD spectrum, especially in light of “recent developments around mitochondrial dysfunction.”
● Reports that some subsets (ie, those with mitochondrial dysfunction) “may be at elevated risk of reduced neurological functioning, possibly including developing ASD, subsequent to vaccination.”
● Reports that, “in the context of vaccination research, the ASD clinical subset of particular interest is regressive autism.”
● Concludes that “public concern regarding vaccines and autism, coupled with the prevalence and severity of ASD, warrant additional study in well defined subpopulations.”
● Will fund studies of environmental risk factors for ASD, such as toxic exposures and "adverse events following immunization (such as fever and seizures), and mitochondrial impairment."
● Will fund studies to determine if some subpopulations are “more susceptible to environmental exposures (e.g., immune challenges related to infections, vaccinations, or underlying autoimmune problems)."
● Will continue to coordinate with the National Vaccine Advisory Committee (NVAC), ”To address public concerns regarding a possible vaccine/ASD link
● Will monitor scientific literature “regarding possible associations of vaccines and other environmental factors with ASD to identify emerging opportunities for research.”
● Concludes that existing population-based vaccine-autism studies were “limited in their ability to detect small susceptible subpopulations.”
● An Institute of Medicine (IOM) committee will consider adverse events from the DtaP vaccine, including autism and autism spectrum disorders, on behalf of VICP.
● The IOM committee will also consider adverse events from the MMR vaccine, including autism and autism spectrum disorders, on behalf of VICP.
● The committee will consider vaccine-associated “secondary” autism or autistic features arising from chronic encephalopathy, mitochondrial disorders and/or other underlying disorders.
● VICP has asked the committee to consider “primary autism” in light of “recent theories of neuro-inflammation and hyper-arousal/over-excitation of the immune system via multiple simultaneous antigenic stimulation” (several vaccines at once).